Dose-Finding Pilot Study of XL184 in Men With Castrate-Resistant Prostate Cancer and Bone Metastases.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Cabozantinib (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Nov 2015 Dosage revised to 20 mg and 40 mg as reported by ClinicalTrials.gov
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jun 2012 Results presented at ASCO 2012, according to an Exelixis media release.